Fennec Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	36.79	26.63	13.27
Cash & Short-Term Investments	36.79	26.63	13.27
Cash Growth	38.12%	100.72%	-
Accounts Receivable	23.22	12.88	8.81
Inventory	1.57	1.06	2.16
Other Current Assets	5.47	3.55	2.62
Total Current Assets	67.04	44.12	26.86
Other Long-Term Assets	3.51	0.82	0.01
Total Assets	70.55	44.95	26.86
Accounts Payable	4.64	3.24	3.78
Accrued Expenses	5.64	3.43	3.75
Current Portion of Leases	-	0	0.02
Unearned Revenue	0.25	0.25	-
Total Current Liabilities	10.52	6.92	7.55
Long-Term Debt	-	19.34	30.93
Other Long-Term Liabilities	24.56	24.56	0
Total Long-Term Liabilities	24.56	43.9	30.93
Total Liabilities	35.08	50.82	38.49
Common Stock	189.91	145.61	144.31
Additional Paid-in Capital	73.75	66.96	62.07
Accumulated Other Comprehensive Income	1.24	1.24	1.24
Retained Earnings	-229.42	-219.68	-219.25
Shareholders' Equity	35.47	-5.87	-11.62
Total Liabilities & Equity	70.55	44.95	26.86
Total Debt	0	19.34	30.95
Net Cash (Debt)	36.79	7.29	-17.68
Net Cash Growth	404.36%	-	-
Net Cash Per Share	1.29	0.27	-0.67
Book Value	35.47	-5.87	-11.62
Book Value Per Share	1.24	-0.22	-0.44
Tangible Book Value	35.47	-5.87	-11.62
Tangible Book Value Per Share	1.24	-0.22	-0.44

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q